March 06, 2015 2:51 AM ET

Biotechnology

Company Overview of aTyr Pharma Inc.

Company Overview

aTyr Pharma Inc. is a protein therapeutics company that discovers and develops biologic therapeutics based on physiocrines. It focuses on the discovery of phyisiocrines, which are a class of endogenous human proteins from amino acyl tRNA synthetases that function as extracellular signaling molecules in various physiologic settings; and the development of physiocrine-based medicines for indications in the areas of hematology, immune modulation, infection, and metabolism. The company’s lead product is Tmax, which is in preclinical development for thrombocytopenia. aTyr Pharma Inc. was incorporated in 2005 and is based in San Diego, California.

3545 John Hopkins Court

Suite 250

San Diego, CA 92121

United States

Founded in 2005

Phone:

858-731-8389

Fax:

858-731-8394

Key Executives for aTyr Pharma Inc.

Executive Chairman and Chief Executive Officer
Age: 54
President and Chief Operating Officer
Founder and Director
Age: 73
Chief Medical Officer
Associate Director of Discovery Research
Compensation as of Fiscal Year 2014.

aTyr Pharma Inc. Key Developments

aTyr Pharma Receives EMA Orphan Drug Designation for Resolaris™ in FSHD

aTyr Pharma Inc. announced the European Commission has granted orphan drug designation to Resolaris for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Resolaris, an investigational new drug representing Physiocrine-based product candidate in the clinic, is being developed as a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. aTyr previously announced the first patient study of Resolaris in adults with FSHD, a rare and severe genetic myopathy for which there are currently no approved treatments. The Phase 1b/2 study is a double-blind, placebo-controlled, multiple ascending dose trial in up to 44 FSHD patients currently enrolling at multiple sites in the European Union (EU). EMA orphan designation is intended to encourage development of medicines for the diagnosis, treatment, or prevention of life-threatening or chronically debilitating conditions that affect no more than 5 in 10,000 people in the EU. Medicines that receive orphan designation are eligible for a number of incentives, including assistance with development of the medicine; reduced fees for marketing-authorization applications; and extended market exclusivity once the medicine is authorized. Orphan designation is conferred following a positive opinion by the EMA's Committee for Orphan Medicinal Products (COMP).

aTyr Pharma Inc. Announces First FSHD Patient Study of Resolaris TM

aTyr Pharma announced its first FSHD patient clinical trial of Resolaris TM, an investigational new drug representing aTyr’s first Physiocrine-based product candidate in the clinic. The study focuses on adult patients with facioscapulohumeral muscular dystrophy (FSHD), a rare and severe genetic myopathy for which there are currently no approved treatments. The Phase 1b/2 study is a double-blind, placebo-controlled, multiple ascending dose trial in up to 44 FSHD patients at multiple sites in the European Union. The exploratory trial is designed to evaluate safety, tolerability, pharmacokinetics and the biological activity of Resolaris TM in adult patients with FSHD.

aTyr Pharma Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-11-2015 08:00 AM

aTyr Pharma Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-11-2015 08:00 AM. Venue: Four Seasons Hotel, 757 Market St, San Francisco, CA 94103. Speakers: John D. Mendlein, Executive Chairman and Chief Executive Officer.

Similar Private Companies By Industry

Company Name Region
Provasculon, Inc. United States
SensiGen, LLC United States
MetroNational Healthcare Ventures United States
Valerion Therapeutics, LLC United States
Biotest Pharmaceuticals Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact aTyr Pharma Inc., please visit www.atyrpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.